Your browser doesn't support javascript.
loading
Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial.
Raftopoulos, Rhian; Hickman, Simon J; Toosy, Ahmed; Sharrack, Basil; Mallik, Shahrukh; Paling, David; Altmann, Daniel R; Yiannakas, Marios C; Malladi, Prasad; Sheridan, Rose; Sarrigiannis, Ptolemaios G; Hoggard, Nigel; Koltzenburg, Martin; Gandini Wheeler-Kingshott, Claudia A M; Schmierer, Klaus; Giovannoni, Gavin; Miller, David H; Kapoor, Raju.
Afiliación
  • Raftopoulos R; National Hospital for Neurology and Neurosurgery, London, UK; University College London Institute of Neurology, London, UK; Queen Square Multiple Sclerosis Centre, London, UK.
  • Hickman SJ; Royal Hallamshire Hospital, Sheffield, UK.
  • Toosy A; National Hospital for Neurology and Neurosurgery, London, UK; University College London Institute of Neurology, London, UK; Queen Square Multiple Sclerosis Centre, London, UK.
  • Sharrack B; Royal Hallamshire Hospital, Sheffield, UK.
  • Mallik S; National Hospital for Neurology and Neurosurgery, London, UK; University College London Institute of Neurology, London, UK; Queen Square Multiple Sclerosis Centre, London, UK.
  • Paling D; National Hospital for Neurology and Neurosurgery, London, UK; University College London Institute of Neurology, London, UK; Royal Hallamshire Hospital, Sheffield, UK.
  • Altmann DR; Queen Square Multiple Sclerosis Centre, London, UK; Medical Statistics Department, London School of Hygiene & Tropical Medicine, London, UK.
  • Yiannakas MC; University College London Institute of Neurology, London, UK; Queen Square Multiple Sclerosis Centre, London, UK.
  • Malladi P; National Hospital for Neurology and Neurosurgery, London, UK.
  • Sheridan R; University College London Institute of Neurology, London, UK.
  • Sarrigiannis PG; Royal Hallamshire Hospital, Sheffield, UK.
  • Hoggard N; Royal Hallamshire Hospital, Sheffield, UK.
  • Koltzenburg M; National Hospital for Neurology and Neurosurgery, London, UK; University College London Institute of Neurology, London, UK.
  • Gandini Wheeler-Kingshott CA; University College London Institute of Neurology, London, UK; Queen Square Multiple Sclerosis Centre, London, UK.
  • Schmierer K; Blizard Institute (Neuroscience), Queen Mary University of London, London, UK; Barts Health NHS Trust, London, UK.
  • Giovannoni G; Blizard Institute (Neuroscience), Queen Mary University of London, London, UK; Barts Health NHS Trust, London, UK.
  • Miller DH; National Hospital for Neurology and Neurosurgery, London, UK; University College London Institute of Neurology, London, UK; Queen Square Multiple Sclerosis Centre, London, UK.
  • Kapoor R; National Hospital for Neurology and Neurosurgery, London, UK; University College London Institute of Neurology, London, UK; Queen Square Multiple Sclerosis Centre, London, UK. Electronic address: r.kapoor@nhs.net.
Lancet Neurol ; 15(3): 259-69, 2016 Mar.
Article en En | MEDLINE | ID: mdl-26822749
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Fenitoína / Neuritis Óptica / Evaluación de Resultado en la Atención de Salud / Fármacos Neuroprotectores / Bloqueadores del Canal de Sodio Activado por Voltaje Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Lancet Neurol Asunto de la revista: NEUROLOGIA Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Fenitoína / Neuritis Óptica / Evaluación de Resultado en la Atención de Salud / Fármacos Neuroprotectores / Bloqueadores del Canal de Sodio Activado por Voltaje Tipo de estudio: Clinical_trials / Prognostic_studies Idioma: En Revista: Lancet Neurol Asunto de la revista: NEUROLOGIA Año: 2016 Tipo del documento: Article